Potential of anti-candida antibodies in immunoprophylaxis

Immunotherapy

Volumn 2, Issue 2, 2010, Pages 171-183

  Cabezas, Jonathan ^a   Albaina, Olatz ^a   Montaez, Dalila ^a   Sevilla, Mara Jess ^a   Moragues, Mara D ^a   Pontn, José ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antibodies; Candida; HSP90; Immunoprophylaxis; Invasive candidiasis; Mycograb ; Treatment

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BETA GLUCAN; CASPOFUNGIN; DIPHTHERIA TOXOID CRM197; FLUCONAZOLE; FLUCYTOSINE; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LAMINARAN; MONOCLONAL ANTIBODY; MYCOGRAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SULFONAMIDE; VORICONAZOLE; BACTERIAL PROTEIN; CRM197 (NON-TOXIC VARIANT OF DIPHTHERIA TOXIN); ECHINOCANDIN; EFUNGUMAB; FUNGUS ANTIBODY; FUNGUS ANTIGEN; FUNGUS VACCINE;

ANTIBODY RESPONSE; ASPERGILLUS FUMIGATUS; BLASTOMYCES DERMATITIDIS; CANDIDA ALBICANS; CANDIDIASIS; CENTRAL VENOUS PRESSURE; COCCIDIOIDES IMMITIS; COLONY FORMING UNIT; CRYPTOCOCCUS NEOFORMANS; DRUG COST; DRUG POTENTIATION; FONSECAEA PEDROSOI; FUNGICIDAL ACTIVITY; FUSARIUM; HISTOPLASMA CAPSULATUM; HUMAN; HYPERTENSION; IMMUNITY; IMMUNOPROPHYLAXIS; IN VITRO STUDY; INFECTION; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PERITONITIS; PHAGOCYTOSIS; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; PULSE PRESSURE; REVIEW; SIDE EFFECT; ADULT; ANIMAL; CHILD; DOUBLE BLIND PROCEDURE; DRUG SCREENING; IMMUNOLOGY; MOUSE; MULTIMODALITY CANCER THERAPY; MYCOSES; PASSIVE IMMUNIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; AMPHOTERICIN B; ANIMALS; ANTIBODIES, FUNGAL; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; BACTERIAL PROTEINS; CANDIDA ALBICANS; CANDIDIASIS; CHILD; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; ECHINOCANDINS; FUNGAL VACCINES; HUMANS; IMMUNIZATION, PASSIVE; MICE; MYCOSES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953440739     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.76     Document Type: Review

References (91)

1. Eggiman P, Garbino J, Pittet D: Epidemiology of Candida species infections in critically ill non-immunocompromised patients. Lancet Infect. Dis. 3, 685-702 (2003).
2. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20, 133-163 (2007).
3. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB: Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin. Infect. Dis. 36, 1103-1110 (2003).
4. Marchetti O, Bille J, Fluckiger U et al.: Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin. Infect. Dis. 38, 311-320 (2004).
5. Fridkin SK: Candidemia is costly-plain and simple. Clin. Infect. Dis. 41, 1240-1241 (2005).
6. Gudlaugsson O, Gillespie S, Lee K et al.: Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37, 1172-1177 (2003).
7. Ostrosky-Zeichner L, Rex JH, Bennett J, Kullberg BJ: Deeply invasive candidiasis. Infect. Dis. Clin. North Am. 16, 821-835 (2002).
8. Pontón J: Usefulness of biological markers in the diagnosis of invasive candidiasis. Rev. Iberoam. Micol. 26, 8-14 (2009).
9. De Pauw B, Walsh TJ, Donnelly JP et al.: Revised defnitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46, 1813-1821 (2008).
10. Leon C, Ruiz-Santana S, Saavedra P et al.: A bedside scoring system ('Candida score') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit. Care Med. 34, 730-737 (2006).
11. Ostrosky-Zeichner L, Sable C, Sobel J et al.: Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur. J. Clin. Microbiol. Infect. Dis. 26, 271-276 (2007).
12. Espinel-Ingroff A: Mechanisms of resistance to antifungal agents: yeasts and flamentous fungi. Rev. Iberoam. Micol. 25, 101-106 (2009).
13. Casadevall A, Scharff MD: Return to the past: the case for antibody-based therapie in infectious diseases. Clin. Infect. Dis. 21, 150-161 (1995).
14. Casadevall A: The third age of antimicrobial therapy. Clin. Infect. Dis. 42, 1414-1416 (2006).
15. Cassone A: Fungal vaccines: real progress from real challenges. Lancet Infect. Dis. 8, 114-124 (2008).
16. Pai JC, Sutherland JN, Maynard JA: Progress towards recombinant anti-infective antibodies. Recent Pat. Antiinfect. Drug Discov. 4, 1-17 (2009).
17. Casadevall A, Pirofski LA: New concepts in antibody-mediated immunity. Infect. Immunol. 72, 6191-6196 (2004).
18. Beckman RA, Weiner LM, Davies HM: Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 109, 170-179 (2007).
19. Odds FC: Candida and Candidosis: A Review and Bibliography. Odds FC (Ed.). Bailliere Tindall, London, UK (1988).
20. Cassone A, De Bernardis F, Torosantucci A: An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Curr. Mol. Med. 5, 377-382 (2005).
21. Bromuro C, Torosantucci A, Chiani P, Conti S, Polonelli L, Cassone A: Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated candidiasis in recipients of a Candida albicans vaccine. Infect. Immun. 70, 5462-5470 (2002).
22. Larsen RA, Pappas PG, Perfect J et al.: Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49, 952-958 (2005).
23. Pachl J, Svoboda P, Jacobs F et al.: A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin. Infect. Dis. 42, 1404-1413 (2006).
24. Matthews RC, Rigg G, Hodgetts S et al.: Preclinical assessment of the effcacy of mycograb, a human recombinant antibody against fungal BCR-ABL90. Antimicrob. Agents Chemother. 47, 2208-2216 (2003).
25. Matthews RC, Burnie JP, Tabaqchali S: Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J. Clin. Microbiol. 25, 230-237 (1987).
26. Hodgetts S, Nooney L, Al-Akeel R et al.: Efungumab and caspofungin: pre-clinical data supporting synergy. J. Antimicrob. Chemother. 61, 1132-1139 (2008).
27. Yang Q, Wang L, Lu DN et al.: Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6J mice. Vaccine 23, 4088-4096 (2005).
28. Wang G, Sun M, Fang J, Yang Q, Tong H, Wang L: Protective immune responses against systemic candidiasis mediated by phage-displayed specifc epitope of Candida albicans heat shock protein 90 in C57BL/6J mice. Vaccine 24, 6065-6073 (2006).
29. ® for the treatment of invasive candidiasis. Clin. Infect. Dis. 43, 1083 (2006).
30. Rowlands HE, Morris K, Graham C: Human recombinant antibody against Candida. Pediatr. Infect. Dis. J. 25, 959-960 (2006).
31. Sutherland A, Ellis D: Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specifc for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin and voriconazole. Peditr. Crit. Care Med. 9, e23-25. (2008).
32. Spronk P, Van der Hoven B, Graham C, et al.: Combination therapy with efungumab for the treatment of invasive Candida infections: several illustrative case reports. Crit. Care 12(Suppl. 2), 20 doi:10.1186/ cc6241 (2008).
33. Saville S P, Lazzel AL, Bryant AP et al.: Inhibition of flamentation can be used to treat disseminated candidiasis. Antimicrob. Agents Chemother. 50, 3312-3316 (2006).
34. Grappel SF, Calderone RA: Effect of antibodies on the respiration and morphology of Candida albicans. S. Afr. Med. J. 14, 51-60 (1976).
35. Brena S, Omaetxebarría MJ, Elguezabal N, Cabezas J, Moragues MD, Pontón J: Fungicidal monoclonal antibody C7 binds to Candida albicans Als3. Infect. Immun. 75, 3680-3682 (2007).
36. Casanova M, Martínez JP, Chaffn WL: Fab fragments from a monoclonal antibody against a germ tube mannoprotein block the yeast-to-mycelium transition in Candida albicans. Infect. Immun. 58, 3810-3812 (1990).
37. Torosantucci A, Bromuro C, Chiani P et al.: A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202, 597-606 (2005).
38. Torosantucci A, Chiani P, Bromuro C et al.: Protection by anti-b-glucan antibodies is associated with restricted b-1,3 glucan binding specifcity and inhibition of fungal growth and adherence. PLoS ONE 4, E5392. doi:10.1371/journal.pone.0005392 (2009).
39. Cowen LE, Lindquist S: BCR-ABL90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309, 2185-2189 (2005).
40. Cowen LE, Singh SD, Köhler JR et al.: Harnessing BCR-ABL90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl Acad. Sci. USA 106, 2818-2823 (2009).
41. Shapiro R, Uppuluri P, Zaas AK et al.: BCR-ABL90 orchestrates temperature-dependent Candida albicans morphogenesis via Ras1-PKA signaling. Curr. Biol. 19, 621-629 (2009).
42. Burnie JP, Carter TL, Hodgetts SJ, Matthews RC: Fungal heat-shock proteins in human disease. FEMS Microbiol. Rev. 30, 53-88 (2006).
43. Polonelli L, Magliani W, Conti S et al.: Therapeutic activity of an engineered synthetic killer anti-idiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71, 6205-6212 (2003).
44. Polonelli L, Ponton J, Elguezabal N et al.: Antibody complementary- determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS ONE 3(6) E2371 (2008).
45. Cassone A, Torosantucci A: Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine. Expert Rev. Vaccines. 5, 859-867 (2006).
46. Casadevall A, Pirofski LA: Polysaccharide-containing conjugate vaccines for fungal diseases. Trends Mol. Med. 12, 6-9 (2006).
47. Cutler JE, Deepe GS, Klein BS: Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 5, 13-28 (2007).
48. Ibrahim AS, Spellberg BJ, Avenissian V, Fu Y, Filler SG, Edwards JE Jr: Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. 73, 999-1005 (2005).
49. Han Y, Cutler JE: Antibody response that protects against disseminated candidiasis. Infect. Immun. 63, 2714-2719 (1995).
50. Xin H, Dziadek S, Bundle DR, Cutler JE: Synthetic glycopeptide vaccines combining b-mannan and peptide epitopes induce protection against candidiasis. Proc. Natl Acad. Sci. USA 105,13526-13531 (2008).
51. Chaturvedi AK, Kavishwar A, Shiva Keshava GB, Shukla PK: Monoclonal immunoglobulin G1 directed against Aspergillus fumigatus cell wall glycoprotein protects against experimental murine aspergillosis. Clin. Diagn. Lab. Immunol. 12, 1063-1068 (2005).
52. Ito JI, Lyons JM, Hong TB et al.: Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis. Infect. Immun. 74, 5075-5084 (2006).
53. Hao W, Pan YX, Ding YQ et al.: Well-characterized monoclonal antibodies against cell wall antigen of Aspergillus species improve immunoassay specifcity and sensitivity. Clin. Vaccine Immunol. 15, 194-202 (2008).
54. Cenci E, Mencacci A, Spreca A et al.: Protection of killer anti-idiotypic antibodies against early invasive aspergillosis in a murine model of a llogeneic T-cell-depleted bone marrow transplantation. Infect. Immun. 70, 2375-2382 (2002).
55. Zhang MX, Brandhorst TT, Kozel TR, Klein BS: Role of glucan and surface protein BAD1 in complement activation by Blastomyces dermatitidis yeast. Infect. Immun. 69, 7559-7564 (2001).
56. Han Y, Riesselman MH, Cutler JE: Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specifc for the same mannotriose as an IgM protective antibody. Infect. Immun. 68, 1649-1654 (2000).
57. Sevilla MJ, Robledo B, Rementeria A, Moragues MD, Ponton J: A fungicidal monoclonal antibody protects against murine invasive candidiasis. Infect. Immun. 74, 3042-3045 (2006).
58. Zhang MX, Bohlman MC, Itatani C et al.: Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect. Immun. 74, 362-369 (2006).
59. Li W, Fu M, An JG et al.: Host defence against C. albicans infections in IgH transgenic mice with V(H) derived from a natural anti-keratin antibody. Cell. Microbiol. 9, 306-315 (2007).
60. Peng T, Shubitz L, Simons J, Perrill R, Orsborn KI, Galgiani JN: Localization within a proline-rich antigen (Ag2/PRA) of protective antigenicity against infection with Coccidioides immitis in mice. Infect. Immun. 70, 3330-3335 (2002).
61. Mukherjee J, Scharff MD, Casadevall A: Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect. Immun. 60, 4534-4541 (1992).
62. Mukherjee J, Pirofski L, Scharff MD, Casadevall A: Antibody mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl Acad. Sci. USA 90,3636-3640 (1993).
63. Rosas AL, Nosanchuk JD, Casadevall A: Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect. Immun. 69, 3410-3412 (2001).
64. Parra C, González JM, Castañeda E, Fiorentino S: Anti-glucuronoxylomannan IgG1 specifc antibodies production in Cryptococcus neoformans resistant mice. Biomedica 25, 110-119 (2005).
65. Rachini A, Pietrella D, Lupo P et al.: An anti-b-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infect. Immun. 75, 5085-5094 (2007).
66. Rodrigues ML, Shi L, Barreto-Bergter E et al.: Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection. Clin. Vaccine Immunol. 14, 1372-1376 (2007).
67. Kondori N, Edebo L, Mattsby-Baltzer I: A novel monoclonal antibody recognizing b(1-3) glucans in intact cells of Candida and Cryptococcus. APMIS 116, 867-876 (2008).
68. Hu ZQ, Li HP, Zhang JB, Glinka E, Liao YC: Antibody-mediated prevention of Fusarium mycotoxins in the feld. Int. J. Mol. Sci. 9, 1915-1926 (2008).
69. Alviano DS, Franzen AJ, Travassos LR et al.: Melanin from Fonsecaea pedrosoi induces production of human antifungal antibodies and enhances the antimicrobial effcacy of phagocytes. Infect. Immun. 72, 229-237 (2004).
70. Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS Jr, Casadevall A: Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J. Clin. Invest. 112, 1164-1175 (2003).
71. Gesztesi JL, Puccia R, Travassos LR et al.: Monoclonal antibodies against the 43,000 Da glycoprotein from Paracoccidioides brasiliensis modulate laminin-mediated fungal adhesion to epithelial cells and pathogenesis. Hybridoma 15, 415-422 (1996).
72. Travassos LR, Silva LR, Rodrigues EG et al.: Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J. Antimicrob. Chem. 54, 956-958 (2004).
73. Gigliotti F, Haidaris GC, Wright TW, Harmsen AG: Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect. Immun. 70, 1069-1074 (2002).
74. Wells J, Haidaris CG, Wright T W, Gigliotti F: Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect. Immun. 74, 2446-2448 (2006).
75. De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G, Cassone A: Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect. Immun. 65, 3399-3405 (1997).
76. Selvakumar D, Karim N, Miyamoto M, Furuichi Y, Komiyama T: Recombinant single-chain anti-idiotypic antibody: an effective fungal b-1,3-glucan synthase inhibitor. Biol. Pharm. Bull. 29, 1848-1853 (2006).
77. Moragues MD, Omaetxebarria MJ, Elguezabal N et al.: A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect. Immun. 71, 5273-5279 (2003).
78. Elguezabal N, Maza JL, Moragues MD, Pontón J: Monoclonal antibody-mediated inhibition of adhesion of Candida albicans and Candida dubliniensis to human epithelial cells. Eur. J. Oral Sci. 117, 474-478 (2009).
79. De Bernardis F, Liu H, O'Mahony R et al.: Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J. Infect. Dis. 195, 149-157 (2007).
80. Coleman DA, Oh S-H, Zhao X et al.: Monoclonal antibodies specifc for Candida albicans Als3 that immunolabel fungal cells in vitro and in vivo and block adhesion to host surfaces. J. Microbiol. Methods 78, 71-78 (2009).
81. Wellington M, Bliss JM, Haidaris CG: Enhanced phagocytosis of Candida species mediated by opsonization with a recombinant human antibody single-chain variable fragment. Infect. Immun. 71, 7228-7231 (2003).
82. Kozel TR, MacGill RS, Percival A, Zhou Q: Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect. Immun. 72, 209-218 (2004).
83. Ishibashi K, Yoshida M, Nakabayashi I et al.: Role of anti-b-glucan antibody in host defense against fungi. FEMS Immunol. Med. Microbiol. 44, 99-109 (2005).
84. Han Y, Kozel TR, Zhang MX, MacGill RS, Carroll MC, Cutler JE: Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental hematogenously disseminated candidiasis. J. Immunol. 167, 1550-1557 (2001).
85. Cutler JE: Defning criteria for anti-mannan antibodies to protect against candidiasis. Curr. Mol. Med. 5, 383-392 (2005).
86. Boxx GM, Nishiya CT, Kozel TR, Zhang MX: Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans. Mol. Immunol. 46, 473-480 (2009).
87. Matthews RC, Burnie JP, Howat D, Rowland T, Walton F: Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis. Immunol. 74, 20-24 (1991).
88. Magliani W, S. Conti S, De Bernardis F et al.: Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nat. Biotechnol. 15, 155-158 (1997).
89. Polonelli L, Séguy N, Conti S et al.: Monoclonal yeast killer toxin-like candidacidal antiidiotypic antibodies. Clin. Diagn. Lab. Immunol. 4,142-146 (1997).
90. Magliani W, Conti S, Giovati L, Maffei DL, Polonelli L: Anti-b-glucan-like immunoprotective candidacidal antiidiotypic antibodies. Front. Biosci. 13, 6920-6937 (2008).
91. Kavishwar A, Shukla PK: Candidacidal activity of a monoclonal antibody that binds with glycosyl moieties of proteins of Candida albicans. Med. Mycol. 44, 159-167 (2006).